Track the Ambrx Biopharma, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 7 March 2024 (Disposition). Among the most active insiders: Nelson Sonja. The full history is free.
8
Insider Decl.
n/a
Thresholds
€9m
1 ops.
Buy Volume
€583,653
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ambrx Biopharma, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
42Σ signal
Buys €9m€583,653 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,307,311 shares@ US$6.9911100.0% of flowCommon StockSEC:0000929638-23-002829:0
Canonical exit: 21 Jan 2024 (T+90)
8 of 8 declarations
Acerca de Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias basadas en proteínas modificadas. Cotiza en el mercado XNAS.